In our current study, we found that HER2‐low breast cancer patients had similar clinicopathological parameters with HER2‐0 rather than HER2‐positive cases, had relatively low sTILs, and had significantly inferior survival in the ER‐negative subgroup. The gene discussed is ERBB2; the disease is breast cancer.